As a key July 1 implementation milestone approaches, most Massachusetts residents support a new state law to provide health coverage to almost all residents, including the individual mandate that requires residents to obtain coverage or pay a penalty, according to a new June poll of 1,003 Massachusetts residents.
At the thought of addressing a classroom or alarger auditorium packed to its capacity some people break out into a sweat, their legs turn to jelly, and their hearts begin to pound wildly or go light-headed.
Health Minister Tony Clement announced that Health Canada is adopting the Trans Fat Task Force?s recommendation on trans fats in Canadian foods, by calling on Canada?s food industry to limit the trans fat content of vegetable oils and soft, spreadable margarines to 2 percent of the total fat content, and to limit the trans fat content for all other foods to 5 percent, including ingredients sold to restaurants.
The body may hold a secret to normalizing skin cell growth that is over zealous in psoriasis and non-melanoma skin cancers and too slow in aging and sun-damaged skin, researchers say.
Advanced Cell Technology, Inc. (OTCBB:ACTC ? News) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist that has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
Prominent Medicare health plans strengthen consumer protections and voluntarily pledge to temporarily suspend non-group PFFS marketing. Statement of AHIP President and CEO Karen Ignagni on landmark industry pledge:
Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated conditional approval for BiovaxID?. The independent Data Monitoring Committee (DMC) has requested an interim analysis of all primary and secondary endpoints.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS).
The Food and Drug Administration has given approval for a Kalamazoo, MI-based company to begin marketing a one-of-a-kind device that allows physicians to more accurately place a stent in selected coronary and renal procedures.